BEND, Ore. (KTVZ) — A Bend high-tech company focused on developing enhanced pharmaceutical drug delivery technology opened a research and development lab earlier this year and is now building a new state-of-the-art facility to support clinical trials. It has just opened. .
Kelsey McGee visits the company to discuss the latest developments. Her reports will be broadcast on her NewsChannel 21 at Five.
Here is the news release announcing the new facility:
Bend Bioscience adds new process and manufacturing science facilities to add manufacturing capacity and technology offerings
BEND, Ore., October 5, 2023 — Bend Biosciences, a preferred partner in drug delivery innovation, development and manufacturing, is pleased to announce the opening of a state-of-the-art pharmaceutical processing and manufacturing science facility.
This approximately 15,000 square foot purpose-built facility is thoughtfully designed to accommodate process identification, development, scale-up, and production of high-quality materials to support clinical trials.
The facility is equipped to maintain Good Manufacturing Practice (GMP) standards and is designed to meet the high quality expectations of both customers and regulators.
With a total of seven state-of-the-art processing suites, this design has the power and capacity to meet the diverse needs of customers. To maintain the highest quality standards for a multi-product facility, each processing suite incorporates a single-pass unidirectional HVAC system with a HEPA filter, including separate inlet and outlet airlocks.
This state-of-the-art facility includes a continuously monitored building automation system with electronic data capture and an on-site GMP quality control laboratory.
Bend Bioscience designed the facility, which includes dedicated visitor and audit hosting space, and is committed to improving the client experience. The versatility of Bend Bioscience’s advanced suite, including solvent-compatible spray drying and low humidity capabilities, gives us the flexibility to provide customized solutions to meet each customer’s unique needs.
“This new facility seamlessly complements our existing R&D innovation lab, enabling us to deliver these innovations and take our clients’ programs to the next level with further process scale-up and GMP manufacturing support. I’m excited.” said Dan Dobry, chief strategy officer of Bend Bioscience and its parent company CoreRx.
“Bend Bioscience invites stakeholders, including potential customers, collaborators, and partners, to visit the new facility and discover the potential it holds for the future of our most important programs. ”